Drug Trial Radar · NCT07365826
A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 With Influenza Vaccine in Adults ≥ 50 Years of Age
Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,390
Actual
Start
Jan 12, 2026
Primary completion
Oct 21, 2026
Study completion Oct 21, 2026
Sponsor
- Lead sponsor
- Vaxcyte, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jan 26, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a Phase 3, randomized, double-blind study to evaluate the safety and immunogenicity of VAX-31 and seasonal influenza vaccine in pneumococcal-naïve adults ≥ 50 years when the two vaccines are administered at the same visit or separately.
Conditions
- Pneumococcal Disease
Interventions
31-valent pneumococcal conjugate vaccineBiological
0.5 mL of VAX-31 will be administered into the deltoid muscle
Seasonal Influenza Vaccine (SIV) (Flublok)Biological
0.5 mL of SIV into the deltoid muscle
PlaceboBiological
0.5mL of placebo (normal saline) into the deltoid muscle
Primary outcomes
What the sponsor says the trial is designed to measure.
- For each of the 32 serotypes (the 31 serotypes included in VAX-31, and serotype 20B), the ratio (co-administration group to sequential administration group) of opsonophagocytic activity (OPA) geometric mean titers (GMT) in evaluable participantsTime frame: 1 Month after VAX-31 vaccination
- For each of the strains in SIV, the ratio (co-administration group to sequential administration group) of hemagglutination inhibition (HAI) GMT in evaluable participantsTime frame: 1 Month after SIV administration
- Percentage of participants reporting solicited local adverse events (AE) within 7 days after Day 1 and Month 1 vaccination (redness, swelling, and pain at injection site) in each groupTime frame: 7 days after each vaccination
- Percentage of participants reporting solicited systemic AE within 7 days after Day 1 and Month 1 vaccination (fever, headache, fatigue, muscle pain, and joint pain) in each groupTime frame: 7 days after each vaccination
- Percentage of participants reporting unsolicited AE within 1 month after Day 1 and Month 1 vaccination in each groupTime frame: 7 days after each vaccination
- Percentage of participants reporting NOCI, MAAE, and SAE within 6 months after last vaccination in each groupTime frame: 6 Months after last vaccination
Locations
25 sites in 1 country. Site status is shown where the registry gives one.
Hope Research Institute
Phoenix, Arizona
Tekton Research at Fort Collins
Fort Collins, Colorado
University Clinical Research - Deland
DeLand, Florida
CenExel Research Centers of America
Hollywood, Florida
Health Awareness
Jupiter, Florida
Accel Research Sites - Lakeland
Lakeland, Florida
Accel Research Sites - Largo
Largo, Florida
Precision Clinical Research
Sunrise, Florida
Velocity Valparaiso
Valparaiso, Indiana
Johnson County ClinTrials
Lenexa, Kansas
AMR Lexington
Lexington, Kentucky
DM Clinical Research - Detroit
Detroit, Michigan
Velocity Omaha
Omaha, Nebraska
Rochester Clinical Research
Rochester, New York
CTI Clinical Research Center
Cincinnati, Ohio
Coastal Carolina Research Center
North Charleston, South Carolina
DelRicht Research - Hendersonville
Hendersonville, Tennessee
AMR Knxoville
Knoxville, Tennessee
Tekton Research at Austin
Austin, Texas
REX Clinical Trials
Beaumont, Texas
Epic Medical Research
DeSoto, Texas
CenExel JBR Clinical Research
Salt Lake City, Utah
Charlottesville Medical Research Center
Charlottesville, Virginia
Health Research of Hampton Roads, Inc.
Newport News, Virginia
Clinical Research Partners, LLC.
Richmond, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.